Seeking Alpha

FDA approves Eliquis label expansion

  • The FDA clears Eliquis (apixaban) for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) and for the reduction in the risk of recurrent DVT and PE following initial therapy.
  • This expands its label beyond its initial indication as a treatment to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation.
  • In 2007, Bristol-Myers Squibb (BMY) and Pfizer (PFE -0.3%) entered into a global collaboration to develop and commercialize apixaban, an oral anticoagulant discovered by BMY.
Comments (1)
  • chicagomary
    , contributor
    Comments (114) | Send Message
    both are also working on ALS drugs and are getting some of the $$ from the ice challenge according to Marketwatch
    21 Aug, 04:57 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector